Moderna, Inc. vs Orphazyme A/S
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. is the larger company by market value: $90.1 B against $7 M for Orphazyme A/S, 12876 times as much (market caps of Oct 30, 2026 for Moderna, Inc. and Jan 5, 2024 for Orphazyme A/S). Orphazyme A/S's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
- Both made a net loss: $2.8 B for Moderna, Inc. and $101 M for Orphazyme A/S.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Moderna, Inc. MRNA · #275 in the world | Orphazyme A/S ORPHA.CO |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇩🇰 Denmark |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2010 | — |
| Size | ||
| Market cap | $90.1 B | $7 M* |
| Revenue | $1.9 B | $0 M |
| Net income | $-2.8 B | $-101 M▲ best |
| Employees | 4,700 | — |
| Valuation | ||
| Price to sales | 35.7× | — |
| Price to book | 10.4× | — |
| Free cash flow yield | -2.3% | — |
| Profitability | ||
| Gross margin | 55.4% | — |
| Operating margin | -158.1% | — |
| Net margin | -145.2% | — |
| Return on equity | -28.9% | — |
| Growth | ||
| Revenue growth | -39.9% | — |
| Revenue growth, 3 years a year | -53.4% | — |
| Financial strength | ||
| Debt to equity | 0.1× | — |
| Cash | ||
| Free cash flow margin | -106.2% | — |
| Shareholder returns | ||
| Shareholder yield | 0.0% | — |
| Strength scores | ||
| Piotroski F-score | 3 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Jan 2024 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Moderna, Inc. or Orphazyme A/S?
Moderna, Inc. is the larger company by market value: $90.1 B against $7 M for Orphazyme A/S, 12876 times as much (market caps of Oct 30, 2026 for Moderna, Inc. and Jan 5, 2024 for Orphazyme A/S). Orphazyme A/S's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
Which makes more money, Moderna, Inc. or Orphazyme A/S?
Both made a net loss: $2.8 B for Moderna, Inc. and $101 M for Orphazyme A/S.
More about Moderna, Inc.
More about Orphazyme A/S
Sources#
Every figure on this page comes from these, with the date shown next to it.